For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
I avoided getting infected with SARS-CoV2 for over 2 years. Now that I have it, I tried to figure out what I should do.
ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third
Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
While the American College of Rheumatology (ACR) recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases (RMD) patients receiving COVID-19 vaccines, there is limited data on such an approach.
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.
The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).
“One faces the future with one’s past” – Pearl S. Buck
2021 was the year we waited for the other shoe to drop; with the pandemic stone in your shoe, you waited for:
The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.
Among immunocompromised individuals vaccinated against COVID-19, solid organ transplant recipients as well as those with HIV and rheumatoid arthritis (RA) were significantly more likely to experience breakthrough infections versus people without immune dysfunction, a retrospective study found.
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
